Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19
and the current standard care relies on supportive treatments. Therefore, based on the fast …
and the current standard care relies on supportive treatments. Therefore, based on the fast …
COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Purpose The coronavirus outbreak emerged as a severe pandemic, claiming more than 0.8
million lives across the world and raised a major global health concern. We survey the …
million lives across the world and raised a major global health concern. We survey the …
COVID-19 infection and rheumatoid arthritis: Faraway, so close!
EG Favalli, F Ingegnoli, O De Lucia, G Cincinelli… - Autoimmunity …, 2020 - Elsevier
The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has
quickly become a global health emergency. Given the lack of specific anti-viral therapies, the …
quickly become a global health emergency. Given the lack of specific anti-viral therapies, the …
COVID-19: drug targets and potential treatments
C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020 - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
[HTML][HTML] Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
P Richardson, I Griffin, C Tucker, D Smith… - Lancet (London …, 2020 - ncbi.nlm.nih.gov
Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute
respiratory disease, there is an immediate need for medicines that can help before a vaccine …
respiratory disease, there is an immediate need for medicines that can help before a vaccine …
COVID-19: combining antiviral and anti-inflammatory treatments
J Stebbing, A Phelan, I Griffin, C Tucker… - The Lancet Infectious …, 2020 - thelancet.com
The Lancet, 3 we described how BenevolentAI's proprietary artificial intelligence (AI)-derived
knowledge graph, 4 queried by a suite of algorithms, enabled identification of a target and a …
knowledge graph, 4 queried by a suite of algorithms, enabled identification of a target and a …
Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality
Y Que, C Hu, K Wan, P Hu, R Wang, J Luo… - International reviews …, 2022 - Taylor & Francis
Abstract The coronavirus disease 2019 (COVID-19) triggered by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December …
syndrome coronavirus 2 (SARS-CoV-2) erupted in Hubei Province of China in December …
Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID‐19
SCJ Jorgensen, CLY Tse, L Burry… - … : The Journal of …, 2020 - Wiley Online Library
A hyperinflammatory response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …
CoV‐2) infection, reminiscent of cytokine release syndrome, has been implicated in the …
Protein–ligand binding with the coarse-grained Martini model
The detailed understanding of the binding of small molecules to proteins is the key for the
development of novel drugs or to increase the acceptance of substrates by enzymes …
development of novel drugs or to increase the acceptance of substrates by enzymes …
Repurposing of kinase inhibitors for treatment of COVID-19
The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …